Supernus Pharmaceuticals, Inc. (SUPN) Institutional Ownership

Ownership Summary

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has 324 institutional investors that have filed 13F reports for the period ending December 2025.

• They owned 100.9% of outstanding stock in December 2025, down from 103.8% the prior quarter.
• They increased total shares held in Supernus Pharmaceuticals by 5.76% from last quarter, and the number of investors in SUPN increased 11.34% annually.
• During the quarter, 172 of these 324 funds increased positions in SUPN, 112 reduced exposure, and 40 held steady.
• In total, institutional investors held 57.09Mn shares in Supernus Pharmaceuticals as of December 2025, up by 3.11Mn shares quarter on quarter, and down 4.01Mn shares year over year.
• BlackRock, Inc. holds the largest position in SUPN at 8.8Mn shares as of December 31, 2025, or 15.56% of shares outstanding.
• The largest buyers of Supernus Pharmaceuticals for the quarter ending December 2025 were VANGUARD PORTFOLIO MANAGEMENT LLC (3.24Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.47Mn), CITADEL ADVISORS LLC (1.04Mn), MILLENNIUM MANAGEMENT LLC (675.91K), Assenagon Asset Management S.A. (530.62K).
• Top sellers of SUPN stock for the quarter ending December 2025 included Point72 Asset Management, L.P. (946.24K), ARMISTICE CAPITAL, LLC (868.65K), Goldman Sachs Group Inc (464.13K), DIMENSIONAL FUND ADVISORS LP (405.31K), ACADIAN ASSET MANAGEMENT LLC (288.53K).
• According to Business Quant data, leading holders of SUPN for December 2025 are BlackRock, Inc. (8.8Mn), MILLENNIUM MANAGEMENT LLC (3.32Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.24Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.47Mn), DIMENSIONAL FUND ADVISORS LP (2.31Mn), State Street Corp (2.29Mn), NOMURA ASSET MANAGEMENT INTERNATIONAL INC. (2.04Mn), ARMISTICE CAPITAL, LLC (1.9Mn), RENAISSANCE TECHNOLOGIES LLC (1.71Mn), GEODE CAPITAL MANAGEMENT, LLC (1.62Mn).